Cantor Fitzgerald Estimates VYGR FY2025 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Voyager Therapeutics in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will post earnings of ($2.20) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $5.73 price target on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $24.63 million during the quarter, compared to analysts’ expectations of $12.63 million. During the same quarter in the prior year, the business posted ($0.59) EPS.

A number of other research analysts also recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Canaccord Genuity Group restated a “buy” rating and set a $14.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Leerink Partners started coverage on shares of Voyager Therapeutics in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target for the company. Wedbush initiated coverage on shares of Voyager Therapeutics in a research note on Friday, November 29th. They issued an “outperform” rating and a $11.00 price objective on the stock. Finally, Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Voyager Therapeutics presently has an average rating of “Buy” and an average target price of $15.97.

Voyager Therapeutics Stock Performance

Shares of VYGR stock opened at $5.22 on Wednesday. The stock’s 50-day moving average is $5.84 and its two-hundred day moving average is $6.67. Voyager Therapeutics has a 1 year low of $4.99 and a 1 year high of $10.66. The firm has a market cap of $285.17 million, a price-to-earnings ratio of 7.35 and a beta of 0.93.

Institutional Trading of Voyager Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. lifted its position in shares of Voyager Therapeutics by 14.5% during the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after acquiring an additional 1,630 shares during the period. Hunter Perkins Capital Management LLC boosted its position in Voyager Therapeutics by 3.3% during the third quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock worth $375,000 after purchasing an additional 2,025 shares in the last quarter. Empowered Funds LLC boosted its position in Voyager Therapeutics by 5.4% during the third quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock worth $262,000 after purchasing an additional 2,278 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Voyager Therapeutics by 2.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 137,477 shares of the company’s stock valued at $804,000 after purchasing an additional 3,473 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Voyager Therapeutics by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after buying an additional 4,098 shares in the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Insider Transactions at Voyager Therapeutics

In other news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the transaction, the chief operating officer now directly owns 112,328 shares of the company’s stock, valued at $634,653.20. This represents a 5.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders sold 10,778 shares of company stock valued at $58,548. Corporate insiders own 4.53% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.